Q4 FY22 Earnings Presentation

Financial summary Revenue by segment Diabetes $584M -7.3% Y/Y Rep -5.4% Y/Y Org2 Total MDT $7,763M -0.2% Y/Y Rep +1.6% Y/Y Org Cardiovascular $2,745M +1.4% Y/Y Rep +3.4% Y/Y Org² Table of Executive Portfolio Financial Guidance & Contents Summary Highlights Highlights Assumptions ESG Appendix Revenue¹ by geography United States $3,939M 0.0% Y/Y Rep 0.0% Y/Y Org² 99 O Non-U.S. Developed $2,438M -3.3% Y/Y Rep +1.2% Y/Y Org² Emerging Markets $1,385M +5.4% Y/Y Rep +7.1% Y/Y Org² GAAP Non-GAAP Neuroscience $2,144M +0.8% Y/Y Rep Diluted EPS $1.10 $1.37 Y/Y % 17% 6% +1.8% Y/Y Org² CC Y/Y % N/A 4% Medical Surgical $2,290M -1.0% Y/Y Rep +1.2% Y/Y Org² +6.2% ex-Vents Y/Y Org² 1Data has been intentionally rounded to the nearest million and, therefore, may not sum. 2Figures represent comparison to Q3 FY21 on a organic basis. 3Operating cash flows less property, plant, and equipment additions. 7 | Q3 FY22 earnings presentation | February 22, 2022 Cash flow from operations YTD $5.3B Free cash flow³ YTD $4.3B Medtronic

View entire presentation